The critical need to accelerate cerebral palsy research with consumer engagement, global networks, and adaptive designs

• Published in: Journal of pediatric rehabilitation medicine Vol. 17; no. 1; pp. 9 - 17
• Main Authors: Thomas, Sruthi P, Novak, Iona, Ritterband-Rosenbaum, Anina, Lind, Karin, Webb, Annabel, Gross, Paul, McNamara, Maria
• Format: Journal Article
• Language: English
• Published: Netherlands IOS Press 26.03.2024
• Subjects: Global Health; Cerebral palsy (CP); adaptive designs; clinical trials; global research networks; consumer engagement
• ISSN: 1874-5393; 1875-8894
• DOI: 10.3233/PRM-240014

The prevalence of cerebral palsy (CP) varies globally, with higher rates and burden of disease in low- and middle-income countries. CP is a lifelong condition with no cure, presenting diverse challenges such as motor impairment, epilepsy, and mental health disorders. Research progress has been made but more is needed, especially given consumer demands for faster advancements and improvements in the scientific evidence base for interventions. This paper explores three strategies to accelerate CP research: consumer engagement, global clinical trial networks, and adaptive designs. Consumer engagement involving individuals with lived experience enhances research outcomes. Global clinical trial networks provide efficiency through larger and more diverse participant pools. Adaptive designs, unlike traditional randomized controlled trials, allow real-time modifications based on interim analyses, potentially answering complex questions more efficiently. The establishment of a CP Global Clinical Trials Network, integrating consumer engagement, global collaboration, and adaptive designs, marks a paradigm shift. The Network aims to address consumer-set research priorities. While challenges like ethical considerations and capacity building exist, the potential benefits for consumers, clinicians, researchers, and funding bodies are substantial. This paper underscores the urgency of transforming CP research methodologies for quicker translation of novel treatments into clinical practice to improve quality of life for those with CP.